Cipla Follows Merck KGaA's Footsteps, Drops Out of Biosimilars Biz
The shakeout on the hotly competitive biosimilars front is continuing.
Just a few weeks after Merck KGaA made its exit from the field after striking a deal to sell off its portfolio of biologic knockoffs to Fresenius for €170 million up front, India’s Cipla says it plans to execute a retreat from biosimilars.
CEO Umang Vohra says he’s looking for partners to pick up on the biosimilar programs it has underway, saying the field is getting too competitive to continue to pump money into R&D.
Just a few weeks after Merck KGaA made its exit from the field after striking a deal to sell off its portfolio of biologic knockoffs to Fresenius for €170 million up front, India’s Cipla says it plans to execute a retreat from biosimilars.
CEO Umang Vohra says he’s looking for partners to pick up on the biosimilar programs it has underway, saying the field is getting too competitive to continue to pump money into R&D.